Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors

Morales, Álvaro; Eidinger, D.; Bruce, Andrew W.

doi:10.1016/s0022-5347(17)58737-6

Cited by 1,639 publications

(855 citation statements)

References 15 publications

Supporting

Mentioning

806

Contrasting

Unclassified

Order By: Relevance

“…As early as the 1970s, patients with localized non-muscle invasive bladder cancer have been treated with intravesical immune therapy with Bacillus Calmette-Guerin (BCG) instillations. 4 Induction intravesical BCG, considered standard of care for high risk non-muscle invasive disease, has multiple mechanisms of actions for anti-tumor activity. These mechanisms include direct infection of tumor cells and initiation of a Th1 mediated immune response with CD4 + T cells and CD8+ cytotoxic T lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

et al. 2018

View full text Add to dashboard Cite

Advanced bladder cancer patients have limited therapeutic options resulting in a median overall survival (OS) between 12 and 15 months. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) has been used successfully in treating patients with metastatic melanoma, resulting in a median OS of 52 months. In this study, we investigated the feasibility of expanding TIL from the tumors of bladder cancer patients. Primary bladder tumors and lymph node (LN) metastases were collected. Tumor specimens were minced into fragments, placed in individual wells of a 24-well plate, and propagated in high dose IL-2 for four weeks. Expanded TIL were phenotyped by flow cytometry and anti-tumor reactivity was assessed after co-culture with autologous tumor digest and IFN-gamma ELISA. Of the 28 transitional cell bladder or LN tumors collected, 14/20 (70%) primary tumors and all of the LN metastases demonstrated TIL expansion. Expanded TIL were predominantly CD3+ (median 63%, range 10–87%) with a median of 30% CD8 + T cells (range 5–70%). TIL secreted IFN-gamma in response to autologous tumor. Addition of agonisitic 4-1BB antibody improved TIL expansion from primary bladder tumors regardless of pre-treatment with chemotherapy. This study establishes the practical first step towards an autologous TIL therapy process for therapeutic testing in patients with bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Intravesical Mycobacterium bovis bacillus Calmette -Guerin (BCG) has been used as an ablative treatment for carcinoma in situ (cis) of the bladder since 1976 (Morales et al, 1976) and is now accepted as a bladdersparing treatment for cis with an early complete response of 70%; 40% of patients remain disease free after 5 years (Griffiths et al, 2002). Intravesical BCG is also widely used as an adjuvant to resection for the prophylaxis of recurrent superficial transitional cell carcinoma (TCC), and may delay progression to invasive disease (Sylvester et al, 2002).…”

mentioning

confidence: 99%

Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy

et al. 2003

View full text Add to dashboard Cite

Intravesical bacillus Calmette -Guerin (BCG) is a treatment for transitional cell carcinoma (TCC) and carcinoma in situ (cis) of the urinary bladder, but some patients remain refractory. The mechanism of cancer clearance is not known, but T cells are thought to play a contributory role. Tissue dendritic cells (DCs) are known to initiate antigen-specific immune responses following activation of receptors, which recognise molecular patterns on the surface of microorganisms. A family of these receptors, the toll-like receptors (TLRs), are also crucial for activating DC to produce cytokines that polarise the T-cell response towards a T helper (Th)1 or Th2 phenotype. This study compared the potential of intact BCG to activate DC with that of the defined TLR4 ligand lipopolysaccharide (LPS) and the TLR9 ligand CpG-oligonucleotide. It was found that all three stimuli efficiently activated normal DC, but cells expressing a mutant TLR4 responded poorly to stimulation with LPS. Importantly, stimulation with BCG induced both IL-12 and IL-10, suggesting subsequent development of a poorly focused T-cell immune response containing both Th1 and Th2 immune function. By contrast, LPS-and CpG-oligonucleotides induced only IL-12, indicating the potential to produce a Th1 response, which is likely to clear cancer most efficiently. Given the toxicity of LPS, our data suggest that CpG-oligonucleotides may be beneficial for intravesical therapy of bladder cancer.

show abstract

“…Es en estos pacientes donde el tratamiento del BCG está indicado, ya que mejoran o se curan con su administración 2 . Estudios a largo plazo con terapia de BCG han reportado respuestas favorables 3,4 .…”

Section: Discussionunclassified

¿La vacuna bcg puede evitar el cáncer de vejiga?

Loarca

Ambrósio

2004

Actas Urológicas Españolas

View full text Add to dashboard Cite

RESUMEN¿LA VACUNA BCG PUEDE EVITAR EL CÁNCER DE VEJIGA? En los países en vía de desarrollo la incidencia de tuberculosis es alta, y la incidencia de cáncer de vejiga es baja. Sobre la base de la utilidad del BCG en la prevención de la TBC y de su uso en el tratamiento y de prevención de las recurrencias del cáncer de vejiga, se investigó la relación entre las 2 patologías. MATERIAL Y MÉTODOS:Se efectuó un estudio retrospectivo y prospectivo. Se revisaron las historias de 52 casos de cáncer de vejiga, se entrevistaron 100 personas, y se entrevistó a médicos que se dedican a tratar pacientes con tuberculosis, sobre la existencia de algún paciente que hubiese tenido las 2 patologí-as o de algún caso vacunado con BCG, que hubiera desarrollado cáncer de vejiga. Éste es un estudio hecho en tres grupos de pacientes, en un periodo de 14 años, entre 1985 y 1999.RESULTADOS: Primer grupo: todos los casos que desarrollaron cáncer de vejiga a ninguno se le había administrado la vacuna de BCG. Segundo grupo: todos los que recibieron la vacuna de BCG como prevención de TBC pulmonar, ninguno desarrollo cáncer de vejiga en el transcurso de una media de 32 años. Tercer grupo: ningún paciente que fue tratado por tuberculosis desarrolló cáncer de vejiga. Ninguno de los médicos entrevistados habían observado caso alguno que hubiera desarrollado las dos patologías, o pacientes que se hubieran vacunado con BCG, que desarrollara cáncer de vejiga.PALABRAS CLAVE: Cáncer de vejiga. BCG. Prevención. ABSTRACT COULD THE BCG VACCINE PREVENT BLADDER CANCER?In developed countries, the incidence of tuberculous is major, and the incidence of bladder cancer is minor. Above the base of the utility of the BCG in the prevention of the tuberculous and the use in the treatment and prevention of the recurrences of cancer, it's investigated the relation between the 2 pathology's. PATIENTS AND METHODS:We effected a study retrospective and prospective. It's revised the history's of 52 cases of bladder cancer, it's interview 100 persons, and interview medicals what to dedicate to treat patients whit tuberculous, above the existence before patient what had the 2 pathology's or before case vaccinate with BCG what to develop bladder cancer. It's a study effected in tree groups of patients, in a period of 14 year, between 1985-1999.

show abstract

Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors

Cited by 1,639 publications

References 15 publications

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy

¿La vacuna bcg puede evitar el cáncer de vejiga?

Contact Info

Product

Resources

About